The US Senate passed a bill over the weekend that could impose tariffs of up to 100% on Indian goods — a sharp escalation from the current 25–50% tariff regime. The trigger: India's continued purchases of Russian crude oil. While the bill must still clear the House and presidential approval, the threat has put India's export-heavy sectors on notice.

Textiles and auto components have dominated tariff coverage so far. But the sector with the largest concentrated US revenue exposure is pharmaceuticals. India supplies roughly 40% of America's generic drug prescriptions, and the biggest Indian pharma companies derive a third to half their revenue from the US market. Here is what their own filings reveal about just how much is at stake.

Aurobindo Pharma: $1.68 Billion in US Formulations

Aurobindo Pharma is perhaps the most US-dependent of India's large pharma companies. Per their Q4 FY24 earnings transcript, US Formulation revenue for the full year reached $1,675 million — a 23% jump over the prior year. The US formulations business represents approximately 85% of total formulation revenue, which itself is about 85% of consolidated sales. In other words, roughly half of Aurobindo's entire revenue comes from the American market.

In Q2 FY25, the company reported US formulation revenues of $421 million for a single quarter. With this kind of concentration, even a partial tariff on pharmaceutical imports would hit Aurobindo disproportionately.

Dr. Reddy's: $1.57 Billion From North America

Dr. Reddy's Laboratories reported North America Generics revenue of $1,568 million for FY24 — a 24% year-over-year increase driven by market share gains and the Mayne portfolio integration, per their Q4 FY24 investor presentation. In Q1 FY26, however, North America revenues fell to Rs 34.1 billion, declining 11% YoY, partly due to price erosion in Lenalidomide.

The company has 73 filings pending approval with the USFDA, including 43 Paragraph IV applications and 22 potential first-to-file opportunities. Dr. Reddy's has also started building a US-based CMO (contract manufacturing organization) for Abatacept, per their FY25 investor presentation — a risk mitigation move that now looks prescient.

Lupin: North America Growing at 23%

Lupin's North America business recorded Rs 25,155 million in Q1 FY26, growing 23% year-over-year, per their earnings presentation. Key US products include Albuterol and Suprep, with the respiratory portfolio holding high market shares. On tariff risk, Lupin's management noted in their Q4 FY25 earnings call that they "don't see a direct impact on brand products" but acknowledged the MFN (Most Favored Nation) order would be "challenging."

The company has been investing in US respiratory launches — generic Advair, Symbicort, and liraglutide are in the pipeline for FY27 — all of which would face margin pressure if import tariffs were applied.

Divi's Laboratories: 70% of Revenue From US and Europe

Divi's Labs occupies a different but equally exposed position in the supply chain. As an API manufacturer and custom synthesis partner, they do not sell finished drugs directly to US consumers — they supply the ingredients. Per their Q1 FY25 earnings transcript, "Exports to US and Europe is about 70%" of total revenue, with overall exports at 86%.

If tariffs are applied to APIs, the pain cascades through the entire supply chain. This is what Clean Science and Technology described in their Q3 FY26 earnings call: "due to secondary impact of tariff of our end customers in India, they have lost their business in the United States, and hence, we are impacted by them as well."

Cipla: Rs 2,271 Crore From North America

Cipla's North America revenue for FY25 stood at Rs 2,270.76 crore, per their FY25 annual report, out of total revenue of Rs 16,111 crore — making the US about 14% of total sales. While that is a lower concentration than Aurobindo or Dr. Reddy's, Cipla's US pipeline is its most valuable growth driver. In their Q4 FY26 earnings presentation, management highlighted upcoming launches: generic Advair, Symbicort, and four peptide assets including liraglutide — all targeting the US market.

The irony is that the US itself depends on Indian generics to keep drug prices affordable. As Sigachi Industries noted in their FY25 annual report: "Proposed tariffs, potentially set at 25% or higher, could result in billions of dollars in additional costs, consequently raising generic prices for consumers in the United States."

Will Pharma Actually Get Tariffed?

Sun Pharma Advanced Research's FY26 annual report flagged the risk plainly: "aggressive US industrial and trade protectionism" and "tariff measures targeting imported pharmaceuticals and APIs created significant uncertainty for global supply chains."

But there is a crucial counterpoint. The US depends on India for about 40% of its generic drug supply. Tariffing these imports would raise healthcare costs for American consumers — politically toxic. Most trade analysts expect essential medicines to be exempted, as they were in earlier tariff rounds. The bill itself is still far from law, requiring House passage and presidential signature.

What Retail Investors Should Do

Do not panic-sell pharma stocks on the headline alone. The 100% tariff is a negotiating threat, not an imminent policy. But do assess your concentration risk. If your portfolio is heavy on US-dependent pharma names like Aurobindo or Dr. Reddy's, the coming weeks will bring volatility until the trade picture clarifies.

Watch for two signals: whether the House takes up the bill, and whether pharma and API imports are explicitly exempted. Companies that have already started diversifying manufacturing to the US — like Dr. Reddy's with its Abatacept CMO — are better positioned than pure-play Indian exporters.

For now, the filings make one thing clear: Indian pharma's US revenue exposure runs into billions of dollars annually. Even the threat of tariffs will weigh on these stocks until clarity emerges.

Data sourced from company filings on NSE via Xaro.